ASCO Annual Meeting | Conference

Fracture Risk Reduced With BPAs During Radium-223/Enzalutamide Treatment in mCRPC

June 8th 2021

Bone-protecting agents utilized during treatment with radium-223 plus enzalutamide reduced the risk for fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.

Regorafenib/Avelumab Combo Elicits Modest Activity in Heavily Pretreated Biliary Tract Cancer

June 8th 2021

The addition of regorafenib to avelumab demonstrated modest anti-tumor responses and survival benefit in patients with heavily pretreated biliary tract cancer.

C-CAR039 Demonstrates Promising Efficacy, Safety in Relapsed/Refractory B-NHL

June 8th 2021

The second-generation 4-1BB bi-specific CAR T-cell therapy C-CAR039 improved response rates and showed favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Panitumumab Plus 5-FU/Leucovorin Maintenance Improves PFS in RAS Wild-Type Metastatic CRC

June 8th 2021

The addition of panitumumab to 5-fluorouracil and leucovorin significantly improved progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.

Trastuzumab Deruxtecan Maintains Antitumor Activity in HER2+ mCRC

June 7th 2021

Final results of the DESTINY-CRC01 trial were consistent with primary analysis, establishing the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-overexpressing metastatic colorectal cancer.

Dr. Zalcberg on the Efficacy of Intra-Patient Dose Escalation With Ripretinib in Advanced GIST

June 7th 2021

John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.

Dr. Tannir on Results With Telaglenastat/Cabozantinib in mRCC

June 7th 2021

Nazir Tannir, MD, FACP, discusses the efficacy of the combination of telaglenastat and cabozantinib in patients with metastatic renal cell carcinoma, as demonstrated in the phase 2 CANTATA trial.

Tisagenlecleucel Induces High Rates of Durable Response in Relapsed/Refractory Follicular Lymphoma

June 7th 2021

Tisagenlecleucel led to a high response rate that proved durable, along with a favorable safety profile, in patients with relapsed/refractory follicular lymphoma following treatment with at least 2 prior regimens, according to interim findings from the phase 2 ELARA trial.

Dr. Ailawadhi on the Efficacy of Lisaftoclax in Hematologic Malignancies

June 7th 2021

Sikander Ailawadhi, MD, discusses the activity of lisaftoclax in patients with hematologic malignancies.

Dr. Short on the Activity of Ponatinib/Blinatumomab in Ph+ ALL

June 7th 2021

Nicholas J. Short, MD, discusses the efficacy of the combination of ponatinib and blinatumomab in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Pembrolizumab Plus Gemcitabine/Hypofractionated Radiotherapy Demonstrates Promising Efficacy in Muscle-Invasive Bladder Cancer

June 7th 2021

Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy appears to be a promising and efficacious, bladder-sparing regimen for patients with muscle-invasive bladder cancer.

Dr. Abou-Alfa on Efficacy With Ivosidenib in IDH1+ Cholangiocarcinoma

June 7th 2021

Ghassan K. Abou-Alfa, MD, discusses the efficacy of ivosidenib in IDH1-mutant cholangiocarcinoma based on the results of the phase 3 ClarIDHy study.

Dr. Litton on Responses to Talazoparib in BRCA1/2+ Early TNBC

June 7th 2021

Jennifer Litton, MD, highlights responses to talazoparib seen in patients with BRCA1/2-positive, early triple-negative breast cancer.

First-Line Ibrutinib/Venetoclax Inhibits Response in CLL/SLL

June 7th 2021

Ibrutinib plus venetoclax produced a complete response and complete response with incomplete bone marrow recovery rate of 56% in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

mFOLFOXIRI/Cetuximab Combo Improves Depth of Response in RAS Wild-Type mCRC

June 7th 2021

Cetuximab added to mFOLFOXIRI induced superior depth of response than mFOLFOXIRI plus bevacizumab in treatment-naïve patients with RAS wild-type metastatic colorectal cancer.

Lisaftoclax Shows Early Safety, Efficacy in Relapsed/Refractory CLL/SLL and Other Hematologic Cancers

June 7th 2021

The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers.

Cetuximab Misses ORR End Point in RAS Wild-Type, BRAF V600E+ mCRC

June 7th 2021

The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mutant metastatic colorectal cancer.

Pertuzumab/Trastuzumab Combo Elicits Clinical Activity in ERBB2/ERBB3+ Uterine Cancer

June 7th 2021

The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer.

Sacituzumab Govitecan Maintains Efficacy Benefit Over Chemo in Metastatic TNBC, Irrespective of Agent

June 7th 2021

The antibody-drug conjugate sacituzumab govitecan retained benefit in progression-free survival, overall survival, and objective response rate over physician’s choice of therapy, regardless of the chemotherapy agent used.

Pembrolizumab/Axitinib Survival Benefit Sustained in Long-Term Results in RCC

June 7th 2021

The frontline combination of pembrolizumab plus axitinib continued to show a survival benefit over single-agent sunitinib in patients with renal cell carcinoma.